QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-maintains-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-87

Oppenheimer analyst Leland Gershell maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the price...

 morgan-stanley-maintains-overweight-on-crinetics-pharmaceuticals-raises-price-target-to-77

Morgan Stanley analyst Jeffrey Hung maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Overweight and raises the pric...

 goldman-sachs-maintains-neutral-on-crinetics-pharmaceuticals-raises-price-target-to-40

Goldman Sachs analyst Richard Law maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Neutral and raises the price ta...

 fda-approves-crinetics-pharmas-first-daily-pill-for-rare-growth-disorder

On Thursday, the U.S.

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

 crinetics-pharmaceuticals-blackberry-perpetua-resources-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceutical...

 assessing-crinetics-pharmaceuticals-insights-from-4-financial-analysts

Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of...

 jmp-securities-maintains-market-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-143

JMP Securities analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Market Outperform and rai...

Core News & Articles

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The ...

 baird-maintains-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-62

Baird analyst Brian Skorney maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Outperform and raises the price target...

 crinetics-pharmaceuticals-receives-fda-approval-for-palsonify-palsonify-is-expected-to-be-available-in-the-us-in-early-october

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) today announced that the U.S.

 jp-morgan-maintains-overweight-on-crinetics-pharmaceuticals-lowers-price-target-to-52

JP Morgan analyst Jessica Fye maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and lowers the price targe...

 jmp-securities-maintains-market-outperform-on-crinetics-pharmaceuticals-lowers-price-target-to-86

JMP Securities analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and lowe...

 crinetics-pharmaceuticals-announces-palsonify-nda-on-track-with-september-25-2025-pdufa-date-has-12b-in-cash-and-investments-as-of-june-30-2025-anticipated-to-provide-runway-into-2029

-SEC Filing

 crinetics-pharmaceuticals-q2-eps-123-misses-108-estimate-sales-1031m-beat-155000k-estimate

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.23) per share which missed the analyst consensus estim...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION